methyl succinyl chloride | 44806-45-3

• 分子结构分类: 有机化合物 - 有机卤素化合物 - 酰卤
• 英文名称: methyl succinyl chloride
• 英文别名: Methylbernsteinsaeure-dichlorid；methylsuccinyl dichloride；methyl-succinyl chloride；Brenzweinsaeuredichlorid；Methyl-succinylchlorid；monomethyl succinyl chloride；2-Methylbutanedioyl dichloride
• CAS: 44806-45-3
• 化学式: C₅H₆Cl₂O₂
• 分子量: 169.007
• InChiKey: XWGXLRRTBBCVMC-UHFFFAOYSA-N

物化性质

• 沸点：
  203.8±13.0 °C(Predicted)
• 密度：
  1.315±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  9
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  34.1
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  methyl succinyl chloride 在 氨 、 苯 作用下， 生成 2-甲基丁二酰胺
  参考文献：
  名称：

  Morrell, Journal of the Chemical Society, 1914, vol. 105, p. 1738

  摘要：

  DOI：
• 作为产物：
  描述：

  甲基丁二酸 在 五氯化磷 作用下， 以 氯仿 为溶剂， 生成 methyl succinyl chloride
  参考文献：
  名称：

  分子旋转差异法在三萜的结构和立体化学问题中的应用

  摘要：

  在105种不饱和四环和五环三萜醇及其简单衍生物的文献中，已通过Barton和Jones分子旋转差法（MRD）进行了关联。通过这样做，所有已知化合物已被诊断为19种立体骨架类型，在某些情况下具有MRD值。将该方法应用于阐明三萜类化合物的结构得到了新的概括。文献中报道的比旋光度值与既定结构不一致的情况，有待进一步研究和纠正，特别是在较严重的情况下。

  DOI：

  10.1016/0040-4020(77)80158-0

文献信息

• Heterocyclic amide compounds and pharmaceutical use of the same
  申请人：The Green Cross Corporation

  公开号：US05948785A1

  公开（公告）日：1999-09-07

  Heterocyclic amide compounds of the formula (I) ##STR1## wherein each symbol is as defined in the specification, pharmacologically acceptable salts thereof, pharmaceutical compositions thereof and pharmaceutical use thereof. The heterocyclic amide compounds and pharmacologically acceptable salts thereof of the present invention have superior inhibitory activity against chymase groups in mammals inclusive of human, and can be administered orally or parenterally. Therefore, they are useful as chymase inhibitors and can be effective for the prophylaxis and treatment of various diseases caused by chymase, such as those caused by angiotensin II.

  式(I)的杂环酰胺化合物##STR1##，其中每个符号如规范中定义的那样，其药理学上可接受的盐，其药物组合物和其药用。本发明的杂环酰胺化合物及其药理学上可接受的盐对哺乳动物包括人类的胰蛋白酶组具有优越的抑制活性，并可经口或经肠外途径给药。因此，它们可用作胰蛋白酶抑制剂，并可有效预防和治疗由胰蛋白酶引起的各种疾病，如由II型血管紧张素引起的疾病。
• CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF
  申请人：Millennium Pharmaceuticals, Inc.

  公开号：US20160031908A1

  公开（公告）日：2016-02-04

  Disclosed are novel compounds and a method of treating a disease associated with aberrant leukocyte recruitment and/or activation. The method comprises administering to a subject in need an effective amount of a compound represented by: or physiologically acceptable salt thereof.

  揭示了新颖的化合物以及治疗与异常白细胞召集和/或激活相关的疾病的方法。该方法包括向需要的受试者施用代表的化合物的有效量： 或其生理上可接受的盐。
• Chemokine receptor anagonists and methods of use therefor
  申请人：Millennium Pharmaceuticals, Inc.

  公开号：US20020169155A1

  公开（公告）日：2002-11-14

  Disclosed are novel compounds and a method of treating a disease associated with aberrant leukocyte recruitment and/or activation. The method comprises administering to a subject in need an effective amount of a compound represented by: 1 or physiologically acceptable salt thereof.

  揭示了新颖的化合物以及一种治疗与异常白细胞召集和/或激活相关疾病的方法。该方法包括向需要的受试者施用化合物1或其生理上可接受的盐的有效量。
• Peptide elastase inhibitors and methods
  申请人：The University of Kentucky Research Foundation

  公开号：US04643991A1

  公开（公告）日：1987-02-17

  Compounds useful as inhibitors of the enzyme elastase are of the following general formula: ##STR1## wherein Z is selected from the group consisting of R"O--Suc-- where R" is lower alkyl of 1 to 3 carbon atoms and CF.sub.3 CO--; X is oxygen or sulfur; R' is selected from the group consisting of straight or secondary branch-chained alkyl of 1 to 4 carbon atoms, alkenyl of 2 to 3 carbon atoms, alkynyl of 2 to 4 carbon atoms, cycloalkyl of 3 to 6 carbon atoms, and benzyl, and R is selected from the group consisting of susbstituted or unsubstituted phenyl wherein the substituents are selected from the group consisting of nitro, and pentafluoro; benzyl, CH.sub.2 CF.sub.2 CF.sub.2 CF.sub.3, 1-lower alkyl tetrazolyl, 1-phenyltetrazolyl, 2-thioxo-3-thiazolidinyl-, pyridyl and benzothiazolyl, provided that when R is paranitrophenyl, R' is other than tertiary-butyl, benzyl or cyclohexyl, and when X is sulfur, R is other than benzyl.

  以下是酶弹性蛋白酶抑制剂的通用公式：##STR1## 其中Z从R"O--Suc--组成的群体中选择，其中R"是1到3个碳原子的低碳烷基和CF.sub.3 CO--; X是氧或硫；R'从1到4个碳原子的直链或次级支链烷基，2到3个碳原子的烯烃基，2到4个碳原子的炔烃基，3到6个碳原子的环烷基和苄基中选择，R从取代或未取代的苯基中选择，其中取代基从硝基和五氟取代基中选择；苄基，CH.sub.2 CF.sub.2 CF.sub.2 CF.sub.3，1-低碳烷基四唑基，1-苯基四唑基，2-硫代-3-噻唑烷基-，吡啶基和苯并噻唑基，条件是当R为对硝基苯基时，R'不是叔丁基、苄基或环己基，且当X为硫时，R不是苄基。
• Chemokine receptor antagonists and methods of use thereof
  申请人：Luly R. Jay

  公开号：US20050070549A1

  公开（公告）日：2005-03-31

  Disclosed are novel compounds and a method of treating a disease associated with aberrant leukocyte recruitment and/or activation. The method comprises administering to a subject in need an effective amount of a compound represented by: formula (1) or physiologically acceptable salt thereof.

  揭示了新化合物和一种治疗与异常白细胞召集和/或激活相关疾病的方法。该方法包括向需要的受试者施用由以下公式（1）表示的化合物或其生理上可接受的盐的有效量。